Susanne Schmidt

Group Leader

University of Bonn
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

2-arachidonoylglycerol (2-AG) is an endogenous modulator of inflammatory processes. Recent studies demonstrate its key role in inflammatory cardiovascular diseases, such as atherosclerosis and left ventricular remodelling. However, whether 2-AG acts as a pro- or anti-inflammatory agent in cardiovascular inflammation is a matter of controversial debate. CD14 + primary human monocytes were treated with 2-AG. Differentially expressed genes were determined by mRNA sequencing and used for bioinformatics analysis of changes in myeloid cell functions and cell signalling pathways. Additionally, we quantified cytokines and mediators involved in cardiac remodelling by multiplexing assays. Human monocytes responded to the treatment with 2-AG by inducing a pro-inflammatory cellular program. The top upregulated hallmark pathways were TNFα signalling via the NF-κB pathway, the inflammatory response and IL-6 signalling, illustrating the pro-inflammatory mode of action of 2-AG. These data were validated at the protein level in the supernatants of stimulated cells using multiplexing assays. Based on these in-vitro results, we examined blood samples from patients during acute and chronic coronary syndromes. By sampling blood from both the periphery and the culprit coronary artery, we observed a trend towards higher local concentrations of the cardiac remodelling factors Galectin-3, Osteopontin, and IP-10 in the coronary arteries of patients presenting with acute coronary syndrome compared with other groups. The levels of these remodelling factors correlate positively with 2-AG levels. Taken together, our data suggest that 2-AG acts as a pro-inflammatory agent in myocardial infarction and LV remodelling.

Year:

2025

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201.Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial.Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability.Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders.Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls.Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials).Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201.Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201.Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201.Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells.Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase.Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells.Fig. S14. ONC201 increases global H3K27me3 in patient samples.Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2025

Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293

Year:

2025

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2024

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2024

H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/CSF correlate samples from patients treated in two completed multi-site clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, while those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle-related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuro-glial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction.

Year:

2024

Myeloid cells play a vital role in innate immune responses as they recognize and phagocytose pathogens like viruses, present antigens, produce cytokines, recruit other immune cells to combat infections, and contribute to the attenuation of immune responses to restore homeostasis. Signal integration by pathogen recognition receptors enables myeloid cells to adapt their functions by a network of transcription factors and chromatin remodelers. This review provides a brief overview of the subtypes of myeloid cells and the main epigenetic regulation mechanisms. Special focus is placed on the epigenomic alterations in viral nucleic acids of HIV and SARS-CoV-2 along with the epigenetic changes in the host’s myeloid cell compartment. These changes are important as they lead to immune suppression and promote the progression of the disease. Finally, we highlight some promising examples of ‘epidrugs’ that modulate the epigenome of immune cells and could be used as therapeutics for viral infections.

Year:

2024

Collaborators (28)

Matthew Hall

Associate Clinical Professor

Florida International University

UNITED STATES
View details

Chandan Kumar

Associate Research Scientist

University of Michigan

UNITED STATES
View details

Adam Resnick

Director

University of Pennsylvania

UNITED STATES
View details

Sebastian Waszak

Tenure Track Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Mariella Filbin

Dana-Farber Cancer Institute

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Yoshie Umemura

Barrow Neurological Institute

UNITED STATES
View details

Rajen J. Mody

University of Michigan

UNITED STATES
View details

minesh mehta

Chair

Florida International University

UNITED STATES
View details

Anna Schwendeman

-

UNITED STATES
View details

Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Michelle M Kim

University of Michigan

UNITED STATES
View details

Sriram Venneti

Professor

University of Michigan

UNITED STATES
View details

Lili Zhao

Professor

Northwestern University

UNITED STATES
View details

Charles Burant

University of Michigan

UNITED STATES
View details

Sabine Mueller

Adjunt Associate Professor

University of California

UNITED STATES
View details

Nathalie Agar

Principal Investigator

Brigham and Women's Hospital

UNITED STATES
View details

Rajan Jain

Professor

NYU Langone Health

UNITED STATES
View details

Matthew Dun

Professor Paediatric Heamatology/Oncology Research

Hunter Medical Research Institute

AUSTRALIA
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Andrea T. Franson

-

UNITED STATES
View details

Javad Nazarian

Lead, DMG Research Center

-

SWITZERLAND
View details

Chan Chung

Principal investigator

Daegu Gyeongbuk Institute of Science and Technology

SOUTH KOREA
View details

Benjamin M Ellingson

Professor

University of California, Los Angeles

UNITED STATES
View details

Daniel R. Wahl

University of Michigan

UNITED STATES
View details

Jacques Grill

Head day care

Gustave Roussy

FRANCE
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

Sharon L Gardner

Associate Professor (Clinical) of Pediatrics

NYU School of Medicine

UNITED STATES
View details